Live Breaking News & Updates on Nasdaq Rna|Page 5

Stay updated with breaking news from Nasdaq rna. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

57,365 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Purchased by Profund Advisors LLC

Profund Advisors LLC acquired a new position in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 57,365 shares of the biotechnology company’s stock, valued at approximately $881,000. Other hedge funds and other institutional investors have also […] ....

Wells Fargo Company , Ameritas Investment Partners Inc , Daiwa Securities Group Inc , Profund Advisors , Exchange Commission , Needham Company , Avidity Biosciences Inc , Avidity Biosciences Company Profile , Credit Suisse Group , Belpointe Asset Management , Avidity Biosciences , Free Report , Asset Management , Investment Partners , Securities Group , Get Free Report , Suisse Group , Visit Holdingschannel , Avidity Biosciences Daily , Nasdaq Rna , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low at $7.65

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $7.65 and last traded at $7.70, with a volume of 205688 shares. The stock had previously closed at $7.97. Analysts Set New Price Targets Several brokerages recently commented on […] ....

Wells Fargo Company , Ancora Advisors , Belpointe Asset Management , Royal Bank , Avidity Biosciences Inc , Credit Suisse Group , Ameritas Investment Partners Inc , Needham Company , Avidity Biosciences Company Profile , Avidity Biosciences , Get Free Report , Suisse Group , Asset Management , Investment Partners , Avidity Biosciences Daily , Nasdaq Rna ,

Analysts Set Avidity Biosciences, Inc. (NASDAQ:RNA) Price Target at $38.83

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has received a consensus rating of “Buy” from the six research firms that are covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective […] ....

Charles Schwab Investment Management Inc , Wells Fargo Company , Avidity Biosciences Inc , Avidity Biosciences Company Profile , Metlife Investment Management , Dimensional Fund Advisors , Vanguard Group Inc , Avidity Biosciences , Get Free Report , Marketbeat Ratings , Wells Fargo , Life Investment Management , Fund Advisors , Charles Schwab Investment Management , Schwab Investment Management , Get Free , Avidity Biosciences Daily , Nasdaq Rna ,

Avidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Rating of "Buy" by Brokerages

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has earned an average rating of “Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages […] ....

United States , American International Group Inc , Daiwa Securities Group Inc , Group Plc , Wells Fargo Company , Ameritas Investment Partners Inc , Avidity Biosciences Company Profile , Avidity Biosciences Inc , Avidity Biosciences , Get Free Report , General Group Plc , State Retirement System , Securities Group , Investment Partners , American International Group , International Group , Get Free , Avidity Biosciences Daily , Nasdaq Rna ,

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Analysts

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has received a consensus rating of “Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target […] ....

Avidity Biosciences Company Profile , Wells Fargo Company , Pricet Rowe Associates Inc , Credit Suisse Group , Avidity Biosciences Inc , Blackrock Inc , Avidity Biosciences , Get Free Report , Suisse Group , Biosciences Stock Down , Get Free , Avidity Biosciences Daily , Nasdaq Rna ,